Emtricitabine

This classification denotes a reverse transcriptase inhibitor and pyrimidine antagonist with the molecular formula C8H10FN3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G70B4ETF4S, chemically known as 5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine but generally known as emtricitabine, which bears US NIH Compound Identifier 60877. European Medicines Agency schedules Emtricitabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01882MIG. The term EMTRICITABINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules emtricitabine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule emtricitabine under HS 29349990 and SITC 51579. As of Q4 2014, EMTRICITABINE remains the US FDA Preferred Term for this commodity. Emtricitabine bears US NLM identifiers UMLS ID C0909839 and NCI Concept Code C47509. SMILES: S1CC(OC1CO)n1cc(F)c(nc1=O)N.